ID   NAT-30
AC   CVCL_U821
SY   NAT 30
DR   cancercelllines; CVCL_U821
DR   Wikidata; Q54907486
RX   PubMed=1368811;
RX   PubMed=3902783;
CC   Group: Hybridoma fusion partner cell line.
CC   Population: African; Kenyan.
CC   Virology: Contains 2 integrated copies of EBV genome on chromosome 1.
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0067 ! Namalwa
SX   Female
AG   Children
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 17
//
RX   PubMed=1368811; DOI=10.1007/BF02525493;
RA   Kuroita T., Tachibana H., Ohashi H., Shirahata S., Murakami H.;
RT   "Growth stimulating activity of heat shock protein 90 alpha to
RT   lymphoid cell lines in serum-free medium.";
RL   Cytotechnology 8:109-117(1992).
//
RX   PubMed=3902783; DOI=10.1007/BF02620891;
RA   Murakami H., Hashizume S., Ohashi H., Shinohara K., Yasumoto K.,
RA   Nomoto K., Omura H.;
RT   "Human-human hybridomas secreting antibodies specific to human lung
RT   carcinoma.";
RL   In Vitro Cell. Dev. Biol. 21:593-596(1985).
//